Table 3.

Effect of financial incentives on viral suppression at 6, 12, and 48 weeks

	Proportion virally suppressed, n/N(%)		Unadjusted Odds Ratio (95% CI)	Adjusted* Odds Ratio (95% CI)	Adjusted P-value
	Intervention group	Control group
Baseline suppressed
6 weeks	147/153 (96%)	134/147 (91%)	2.38 (0.88–6.43)	3.62 (1.14–11.47)	0.03
12 weeks	143/153 (93%)	128/147 (87%)	2.12 (0.95–4.73)	2.30 (0.99–5.30)	0.05
48 weeks	144/153 (94%)	128/147 (87%)	2.38 (1.04–5.44)	3.00 (1.21–7.44)	0.02
Baseline unsuppressed
6 weeks	16/48 (33%)	10/44 (23%)	1.7 (0.67–4.29)	2.01 (0.73–5.55)	0.18
12 weeks	22/48 (46%)	21/44 (48%)	0.93 (0.41–2.10)	0.98 (0.40–2.38)	0.96
48 weeks	32/48 (67%)	26/44 (59%)	1.38 (0.59–3.24)	1.40 (0.57–3.46)	0.46

Notes: results based on intention-to-treat analyses, viral suppression defined as HIV RNA <400 copies per mL

^*Adjusted for gender and median daily wage